Creatine on GLP-1 Medications: Does It Preserve Muscle?

Ask any fitness forum, telehealth clinic, or supplement brand what to take alongside semaglutide or tirzepatide, and the answer arrives faster than the question finishes: creatine. Taking creatine on GLP-1 medications has become the default recommendation for anyone worried about losing muscle along with fat — a claim now attached to nearly every creatine product marketed since 2024.

The recommendation is not baseless. Creatine monohydrate has one of the deepest evidence bases in sports nutrition, and the biology transfers plausibly to a person eating 1,200 calories a day on a weekly injection. But "plausible" and "demonstrated" are different standards, and the gap between them is where this article lives.

The Problem Creatine Is Supposed to Solve

Weight lost on incretin therapy is not purely fat. Across published trials, lean body mass accounts for roughly a quarter to a third of total weight lost on semaglutide and tirzepatide — a proportion broadly comparable to diet-induced weight loss, but occurring far faster and in far more people.

The SEMALEAN study followed 106 patients with obesity (mean BMI 46.3) through 12 months of semaglutide 2.4 mg, and its results are the most useful framing available: the losses are real, front-loaded, and not uniformly harmful.

Evidence: "Total fat mass decreased by 14% at M7 and 18% at M12... Lean mass declined by 3 kg at M7 then stabilized. Handgrip strength improved significantly (+4.5 kg at M12), and the prevalence of sarcopenic obesity fell from 49% at baseline to 33%." — Alissou M, et al. Diabetes, Obesity and Metabolism. 2026. DOI: 10.1111/dom.70141

Two things in that result matter for the creatine question. Lean mass fell but then plateaued, and muscle function improved even as muscle mass dropped — because carrying 20 fewer kilograms makes the remaining muscle more capable. The concern is therefore not that lean mass loss is catastrophic by default. It is that in older patients, in those losing weight very fast, and in anyone doing no resistance training, the losses compound in a body that has less reserve to spare. Our detailed breakdown of muscle loss on GLP-1 medications covers who is actually at risk.

How Creatine Works in Muscle

Creatine is not a hormone, a stimulant, or a steroid. Roughly 95% of the body's supply sits in skeletal muscle, most of it bound as phosphocreatine — a phosphate reservoir that regenerates ATP during short, high-intensity effort.

Supplementation raises intramuscular creatine and phosphocreatine stores by 20–40% in most people. The downstream effect is mechanical rather than metabolic: more available phosphate means more repetitions before failure, more total training volume, and over weeks, greater training adaptation. The International Society of Sports Nutrition summarized the position more than a decade after the primary literature settled.

Evidence: "Creatine monohydrate is the most effective ergogenic nutritional supplement currently available to athletes in terms of increasing high-intensity exercise capacity and lean body mass during training." — Kreider RB, et al. Journal of the International Society of Sports Nutrition. 2017. DOI: 10.1186/s12970-017-0173-z

The phrase "during training" is doing considerable work in that sentence, and it is the hinge on which the entire GLP-1 recommendation turns.

What the Creatine Evidence Actually Shows

Two large meta-analyses published within months of each other give a clear read on effect size.

The Journal of Strength and Conditioning Research pooled 12 randomized trials in adults under 50 who were resistance training, comparing creatine plus training against training alone.

Evidence: "Compared with resistance training alone, creatine supplementation increased lean body mass by 1.14 kg (95% CI 0.69 to 1.59), reduced body fat percentage by −0.88% (95% CI −1.66 to −0.11) and body fat mass by −0.73 kg (95% CI −1.34 to −0.11)." — Desai I, et al. Journal of Strength and Conditioning Research. 2024. DOI: 10.1519/JSC.0000000000004862

A broader GRADE-assessed review swept in 143 randomized trials regardless of whether participants trained, and the numbers shrank accordingly — fat-free mass rose by 0.82 kg and body fat percentage fell by 0.28%, with the authors noting the findings were more robust when creatine was paired with resistance training.

Population	Trials	Lean/fat-free mass effect	Fat effect
Adults under 50, all resistance training	12	+1.14 kg vs training alone	−0.73 kg, −0.88% body fat
All adults, training or not	143	+0.82 kg	−0.28% body fat
Aged adults, resistance training	6	SMD 0.27 (small, significant)	Not the primary outcome

The third row deserves attention, because GLP-1 patients skew older than the sports nutrition literature. A 2025 meta-analysis in older adults found a statistically significant but genuinely modest pooled effect on lean tissue — and one that faded with time.

Evidence: "Creatine supplementation combined with resistance training significantly improved lean tissue mass (SMD = 0.27, 95% CI 0.02–0.53). Subgroup analysis showed a significant effect for short-term interventions (≤32 weeks: SMD = 0.57) but not long-term (≥52 weeks: SMD = 0.08)." — Liu S, et al. European Review of Aging and Physical Activity. 2025. DOI: 10.1186/s11556-025-00392-9

So the honest summary of decades of research is this: creatine reliably adds around one kilogram of lean mass over placebo in people who lift weights, produces a fraction of that in people who do not, and the benefit in older adults is smaller and may attenuate past a year.

Creatine on GLP-1 Medications: What Is Actually Known

Here is the part the marketing skips. As of mid-2026, no published randomized controlled trial has tested creatine supplementation in patients taking a GLP-1 receptor agonist.

Every claim that creatine preserves lean mass on semaglutide or tirzepatide is an extrapolation from trials conducted in populations that differ in three ways that plausibly matter:

Energy balance. Most creatine trials were run in weight-stable or weight-gaining participants. Muscle protein synthesis behaves differently in a 750-calorie daily deficit, and creatine does not supply amino acids.
Protein intake. Trial participants typically ate adequate or high protein. GLP-1 patients frequently do not — reduced appetite cuts total intake, and protein is often the first thing to fall. Creatine cannot substitute for the substrate.
Training status. The 1.14 kg figure comes exclusively from people performing structured resistance training. The subset of GLP-1 patients doing progressive resistance work is considerably smaller than the subset buying creatine.

That last point is the practical crux. In the meta-analytic data, resistance training is not a modifier that improves creatine's effect — it is close to a precondition for it. A patient adding creatine to a sedentary routine is buying the 0.82 kg average from the all-comers analysis at best, and possibly less in a deficit.

None of this makes creatine a bad choice. It makes it a secondary one. The interventions with direct evidence in this population are progressive resistance training and adequate protein intake — 1.2 to 1.6 g/kg of body weight per day is the range most commonly recommended during medically supervised weight loss, and hitting it on a suppressed appetite is difficult enough that protein supplementation is frequently the more consequential purchase. Creatine sits on top of that foundation. It does not replace it.

The Lean Mass Measurement Confound

One nuance rarely mentioned in supplement copy: creatine draws water into muscle cells. Intracellular hydration rises, and because DXA and bioimpedance scans classify water as lean tissue, some portion of the measured "lean mass gain" on creatine is fluid rather than contractile protein.

This is not evidence that creatine does nothing — the strength and performance gains are real and are not explained by water. But it does mean that a body composition scan showing preserved lean mass after starting creatine overstates the tissue-level benefit, and that anyone tracking DXA numbers on a GLP-1 should interpret an early lean mass bump with appropriate skepticism.

Dosing, Safety, and Practical Use

Dosing is settled and unglamorous. Creatine monohydrate is the only form with a serious evidence base; the buffered, hydrochloride, and liquid variants sold at a premium have not outperformed it.

Protocol	Dose	Duration	Notes
Loading	20 g/day, split into 4 doses	5–7 days	Saturates stores fastest; more GI upset
Maintenance	3–5 g/day	Ongoing	Standard approach
No-load	3 g/day	28 days to saturation	Same endpoint, gentler on the gut

For GLP-1 patients, the no-load protocol is the sensible default. Nausea, early satiety, and delayed gastric emptying are already common on these drugs, and a 20 g loading dose is a reliable way to make that worse for no clinical gain — saturation arrives either way.

Safety

The safety record is the strongest part of creatine's case. A pooled safety analysis across 951 participants taking 1–30 g per day for periods ranging from 4 days to a full year recorded no deaths and no serious adverse events. The persistent claims about kidney damage and hair loss have been examined directly and are not supported in healthy individuals.

Evidence: "There is no compelling scientific evidence that the short- or long-term use of creatine monohydrate has any detrimental effects on otherwise healthy individuals... creatine supplementation does not increase the risk of hair loss, dehydration, muscle cramping, or renal dysfunction." — Antonio J, et al. Journal of the International Society of Sports Nutrition. 2021. DOI: 10.1186/s12970-021-00412-w

Two caveats specific to this population. Creatine raises serum creatinine — a metabolic byproduct, not kidney injury — which can produce an alarming eGFR reading and trigger an unnecessary workup. Tell your prescriber you are taking it before routine labs, particularly relevant given that many GLP-1 patients are monitored for kidney function as part of diabetes care. And anyone with pre-existing renal disease should clear creatine with their physician rather than assuming the healthy-population safety data applies.

Hydration deserves a mention too. Creatine increases intracellular water demand at a time when GLP-1 patients are already prone to reduced fluid intake. Adequate hydration is not optional here.

Key Takeaways

Creatine is a reasonable adjunct on GLP-1 therapy, priced at a few dollars a month, with a safety record better than most things in a pharmacy. It is also considerably less proven for this specific use than the marketing implies.

The direct evidence does not exist. No randomized trial has tested creatine in patients on semaglutide, tirzepatide, or any incretin therapy. Every recommendation is extrapolation from different populations.
The effect size is about 1 kg, and it is conditional. Creatine added roughly 1.14 kg of lean mass over resistance training alone in adults under 50. Without training, the pooled effect drops to 0.82 kg across all trials — and in older adults it is smaller still, with the benefit fading beyond a year.
Resistance training and protein come first. Both have direct evidence in weight loss populations. Creatine amplifies a training stimulus; it does not create one, and it supplies no amino acids.
Skip the loading phase. Three grams daily reaches the same saturation in four weeks without stacking GI side effects onto a drug that already causes them.
Warn your prescriber before bloodwork. Creatine elevates serum creatinine without harming the kidney, and an unexplained eGFR drop on a GLP-1 is exactly the kind of finding that leads somewhere unnecessary.

The realistic framing is that creatine is a low-cost, low-risk addition that might modestly improve the quality of weight lost in someone already lifting weights and eating enough protein. For someone doing neither, it is a supplement purchased in place of the two interventions that actually work.

References

Alissou M, Demangeat T, Folope V, et al. Impact of semaglutide on fat mass, lean mass and muscle function in patients with obesity: the SEMALEAN study. Diabetes, Obesity and Metabolism. 2026;28(1):112-121. DOI: 10.1111/dom.70141
Desai I, Wewege MA, Jones MD, et al. The effect of creatine supplementation on resistance training-based changes to body composition: a systematic review and meta-analysis. Journal of Strength and Conditioning Research. 2024;38(10):1813-1821. DOI: 10.1519/JSC.0000000000004862
Pashayee-Khamene F, Heidari Z, Asbaghi O, et al. Creatine supplementation protocols with or without training interventions on body composition: a GRADE-assessed systematic review and dose-response meta-analysis. Journal of the International Society of Sports Nutrition. 2024;21(1):2380058. DOI: 10.1080/15502783.2024.2380058
Liu S, Huang N, Wu W, et al. The impact of creatine supplementation associated with resistance training on muscular strength and lean tissue mass in the aged: a systematic review and meta-analysis. European Review of Aging and Physical Activity. 2025;22:26. DOI: 10.1186/s11556-025-00392-9
Kreider RB, Kalman DS, Antonio J, et al. International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine. Journal of the International Society of Sports Nutrition. 2017;14:18. DOI: 10.1186/s12970-017-0173-z
Antonio J, Candow DG, Forbes SC, et al. Common questions and misconceptions about creatine supplementation: what does the scientific evidence really show? Journal of the International Society of Sports Nutrition. 2021;18(1):13. DOI: 10.1186/s12970-021-00412-w
Antonio J, Brown AF, Candow DG, et al. Part II. Common questions and misconceptions about creatine supplementation: what does the scientific evidence really show? Journal of the International Society of Sports Nutrition. 2025;22(1):2441760. DOI: 10.1080/15502783.2024.2441760
Candow DG, Vogt E, Johannsmeyer S, Forbes SC, Farthing JP. Strategic creatine supplementation and resistance training in healthy older adults. Applied Physiology, Nutrition, and Metabolism. 2015;40(7):689-694. DOI: 10.1139/apnm-2014-0498

Last updated: 2026-07-26 Medical review: Dr. James Chen, MD, PhD, FACE